TransCode Therapeutics, Inc., a biotech company, has been the subject of a Schedule 13G amendment filing with the United States Securities and Exchange Commission (SEC) as of December 31, 2023. The filing was made by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, collectively referred to as the Reporting Persons. According to the filing, each of the Reporting Persons owns 26,279 shares of TransCode Therapeutics' common stock, which represents 0.1% of the class. The filing indicates that Lind Global Partners II LLC, as the general partner of Lind Global Fund II LP, and Jeff Easton, as the managing member of Lind Global Partners II LLC, have sole voting and dispositive power over the shares held by Lind Global Fund II...Show More

TransCode Therapeutics, Inc., a biotech company, has been the subject of a Schedule 13G amendment filing with the United States Securities and Exchange Commission (SEC) as of December 31, 2023. The filing was made by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, collectively referred to as the Reporting Persons. According to the filing, each of the Reporting Persons owns 26,279 shares of TransCode Therapeutics' common stock, which represents 0.1% of the class. The filing indicates that Lind Global Partners II LLC, as the general partner of Lind Global Fund II LP, and Jeff Easton, as the managing member of Lind Global Partners II LLC, have sole voting and dispositive power over the shares held by Lind Global Fund II LP. The principal business office for all Reporting Persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, dated February 13, 2024, includes a certification that the shares were not acquired for the purpose of changing or influencing the control of the issuer and were not held in connection with any transaction having that purpose or effect.